Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0K0OZ
|
||||
Former ID |
DAP000341
|
||||
Drug Name |
Famotidine
|
||||
Synonyms |
Amfamox; Antodine; Apogastine; Bestidine; Blocacid; Brolin; Cepal; Confobos; Cronol; Cuantin; Digervin; Dinul; Dipsin; Dispromil; Dispronil; Duovel; Durater; Evatin; Fadin; Fadine; Fadyn; Fagastine; Famo; Famocid; Famodar; Famodil; Famodin; Famodine; Famogard; Famonit; Famopsin; Famos; Famosan; Famotal; Famotep; Famotin; Famovane; Famowal; Famox; Famoxal; Famtac; Famulcer; Fanobel; Fanosin; Fanox; Farmotex; Ferotine; Fibonel; Fluxid; Fudone; Ganor; Gaster; Gastridan; Gastridin; Gastrion; Gastro; Gastrodomina; Gastrofam; Gastropen; Gastrosidin; Hacip; Huberdina; Ingastri; Invigan; Lecedil; Logos; Mensoma; Midefam; Mosul; Motiax; Muclox; Neocidine; Nevofam; Notidin; Nulceran; Nulcerin; PEPCID; Panalba; Pepcidac; Pepcidin; Pepcidina; Pepcidine; Pepdif; Pepdine; Pepdul; Pepfamin; Peptan; Peptidin; Peptifam; Pepzan; Purifam; Quamatel; Quamtel; Renapepsa; Restadin; Rogasti; Rubacina; Sigafam; Supertidine; Tairal; Tamin; Tipodex; Topcid; Ulcatif; Ulceprax; Ulcofam; Ulfagel; Ulfam; Ulfamid; Ulfinol; Ulgarine; Vagostal; Weimok; Whitidin; Yamarin; FAMOTIDINE PRESERVATIVE FREE; FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER; Famotidina [Spanish]; Famotidinum [Latin]; Mylanta AR; PEPCID COMPLETE; PEPCID PRESERVATIVE FREE; PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER; Pepcid AC; Pepcid AC Gelcaps; PepcidRPD; Pepcidin Rapitab; Dibrit 40; F 6889; F0530; L 643341; MK 208; YM 11170; Apo-Famotidine; HS-0054; MK-208; Novo-Famotidine; Nu-Famotidine; Pepcid (TN); Pepcidine (TN); Sedanium-R; YM-11170; YM-1170; Famotidine [USAN:BAN:INN:JAN]; Propanimidamide, 3-[[[2-[aminoiminomethyl)amino]-4-thiazoyl]methyl]thio]-N-(aminosulfonyl); N'-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine; (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide; (1Z)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide; (1Z)-N'-(aminosulfonyl)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)thio]propanimidamide; 3-(2-Guanidinothiazol-4-ylmethylthio)-N1-sulfamoylpropionamide; 3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpro; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Antiulcer Agents
|
||||
Company |
Astellas Pharma
|
||||
Structure |
Download2D MOL |
||||
Formula |
C8H15N7O2S3
|
||||
InChI |
InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
|
||||
InChIKey |
XUFQPHANEAPEMJ-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 76824-35-6
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
219459, 855518, 7847384, 7979217, 10321312, 11111194, 11111195, 11736775, 12013748, 14777800, 14900130, 14900131, 17405060, 24278442, 26719681, 26753575, 46386903, 47350438, 47425376, 47721689, 47957418, 48108291, 48244468, 48407560, 48415998, 49681730, 49698346, 49835099, 49846705, 50022089, 50100994, 50100995, 50106279, 50106280, 53777603, 57364911, 76715592, 77320398, 81093272, 85211955, 85220228, 85231052, 87558227, 90340682, 90501992, 91704175, 92125054, 92303791, 92308237, 92308848
|
||||
ChEBI ID |
ChEBI:4975
|
||||
SuperDrug ATC ID |
A02BA03
|
||||
SuperDrug CAS ID |
cas=076824356
|
||||
Target and Pathway | |||||
References | |||||
Ref 537645 | Clinical review of histamine2 receptor antagonists. Arch Intern Med. 1990 Apr;150(4):745-51. | ||||
Ref 542080 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7074). | ||||
Ref 534993 | Blastocyst H(2) receptor is the target for uterine histamine in implantation in the mouse. Development. 2000 Jun;127(12):2643-51. | ||||
Ref 535112 | Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5. | ||||
Ref 535379 | Analysis of Vancomycin in the Hindlimb Vascular Bed of the Rat. Am J Ther. 1996 Oct;3(10):681-687. | ||||
Ref 537690 | Pharmacological control of the human gastric histamine H2 receptor by famotidine: comparison with H1, H2 and H3 receptor agonists and antagonists. Eur J Clin Invest. 1989 Feb;19(1):1-10. | ||||
Ref 538084 | Effect of the H2 histamine receptor antagonist on oxygen metabolism in some morphotic blood elements in patients with ulcer disease. Hepatogastroenterology. 1998 Jan-Feb;45(19):276-80. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.